Immune responses are defective in patients with leukemia because of the presence of powerful immune-suppressive circuits activated by soluble factors and immune-checkpoint molecules, including PD-L1, TIM-3, and Indoleamine-pyrrole 2,3-dioxygenase-138,39. The gene discussed is CD274; the disease is leukemia.